Full-Time

Quality Control Project Manager

Bachem

Bachem

1,001-5,000 employees

Develops and manufactures peptides and oligonucleotides

Compensation Overview

$98.4k - $135.3k/yr

+ Bonus

Carson, CA, USA

In Person

Category
Business & Strategy (1)
Required Skills
Data Analysis
Requirements
  • Bachelor's degree in chemistry or a related life sciences field
  • 5+ years' QC experience in biotech/pharma
  • 3+ years’ experience in a biotech/pharma CDMO setting
  • Extensive experience with analytical techniques/instruments, including Gas Chromatography, High Performance Liquid Chromatography, Karl Fischer, etc.
  • Ability to coordinate and maintain contracted vendor services and work assignments.
Responsibilities
  • Manage customer projects and serve as the primary Quality Control point of contact for project-related activities, ensuring timely execution, cross-functional coordination, and compliance with GMP and regulatory requirements.
  • Oversee critical testing activities at the Torrance site, including stability studies and other regulatory-driven testing requirements.
  • Support departmental leadership in project prioritization, resource planning, and allocation to ensure efficient execution of QC activities and project deliverables.
  • Coordinate testing activities between Bachem sites to support timely product and service delivery while contributing to achievement of weekly operational and financial targets.
  • Lead cross-functional resolution of testing issues at contract sites, including deviations and laboratory investigations, ensuring timely escalation, risk assessment, and effective resolution in alignment with quality and regulatory expectations.
  • Lead customer communications with RA, QA, Project Management, and other stakeholders on stability issues, data trends, specification setting, and regulatory inquiries, ensuring clear escalation, alignment, and timely resolution of quality-related matters.
  • Lead the authoring, review, and approval of project-related protocols, reports, and associated technical documentation, ensuring scientific accuracy, regulatory compliance, and alignment with GMP requirements.
  • Lead and actively contribute to continuous improvement initiatives within the QC laboratory, including development and monitoring of KPIs to drive operational efficiency, compliance, and performance excellence.
Desired Qualifications
  • 4+ years of project management experience in a GMP environment
  • Excellent presentation skills

Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bubendorf, Switzerland

Founded

1971

Your Connections

People at Bachem who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • US biotech demand supports custom peptides, especially GLP-1 and oncology programs.
  • Building K and Sisslerfeld expand capacity toward CHF 1 billion sales.
  • TIRmed and SpheriTech partnerships broaden revenue beyond standard peptide contracts.

What critics are saying

  • Commissioning slippage at Building K or Sisslerfeld would quickly destroy margin expansion.
  • US biotech funding freezes directly reduce Bachem's custom peptide backlog.
  • FDA or EMA manufacturing failures would halt capacity and trigger customer exits.

What makes Bachem unique

  • Bachem leads peptide and oligonucleotide CDMO work for pharmaceutical customers worldwide.
  • Anne-Kathrin Stoller became CEO on 2026-01-01, bringing Americas operating experience.
  • The company secured a CHF 500 million revolving facility on 2026-04-27.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Company News

Nordic Life Science
Nov 18th, 2025
TIRmed Pharma collaborates with Bachem

TIRmed Pharma collaborates with Bachem. The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed's treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials. As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release. With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company. "The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic," says Leo Holmgren, CEO of TIRmed Pharma. "It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative," he adds. Learn more about the science behind TIRmed Pharma and its connections to this year's Nobel Prize in Medicine in our latest issue of the magazine - out now!

CHEManager
Oct 31st, 2025
Anne-Kathrin Stoller Becomes New CEO at Bachem

Anne-Kathrin Stoller becomes new CEO at Bachem. Bachem announced today that the Board of Directors has appointed Anne-Kathrin Stoller, the former Head of Bachem Americas and previously the company's CMO for many years, as the new CEO effective january 1, 2026. She succeeds Thomas Meier, who has decided to take on a new challenge outside the company after more than thirty years at Bachem and almost six years as CEO. "Thomas Meier has contributed significantly to Bachem's continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem's position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem," says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: "I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem's successful course." Thomas Meier, CEO, Bachem, added: "Bachem is a great company and has developed into a leading global, innovation-driven developer and manufacturer of peptides and oligonucleotides in recent years. I have had the privilege of helping to shape and accompany this development in various roles over the past three decades, and I am very grateful for the many enriching experiences I have had at work and the formative encounters with people. Above all, I would like to thank Bachem's employees and customers, as well as my colleagues in the Executive Committee and on the Board of Directors, for their active support and excellent cooperation." Anne-Kathrin Stoller, current Head of Bachem Americas and future CEO, Bachem, commented: "I am delighted to have earned the trust of the Board of Directors and will do everything in my power, together with the members of the Executive Committee and all Bachem employees, to continue our company's impressive success story. Under the leadership of Thomas Meier, Bachem has set the course for the future. I would like to thank him for his collegial support over the past years and everyone at Bachem who works hard every day to ensure that we make an important contribution to human health." Anne-Kathrin Stoller has worked for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer and member of the Group Executive Board, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company's US business. Anne-Kathrin Stoller studied chemistry in Hanover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

Stock Titan
Aug 20th, 2025
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role

Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025.

Stock Titan
Jul 24th, 2025
Bachem Shows Strong Growth in the First Half of 2025

Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.

PharmiWeb.com
Nov 27th, 2024
Green Manufacturing In Pharma: Sustainable Oligonucleotide Production On An Industrial Scale

Oligonucleotides are at the forefront of modern medicine, and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides – short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics – have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met. Demand for oligonucleotides in medicines is steadily increasing, with pressing need for an eco-friendly manufacturing process which satisfies green manufacturing standards without compromising yield or process efficiency. Thus, the responsibility lies with manufacturers to ensure end users receive their medications, while striving for sustainable production methods